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ABSTRACT
Although mechanisms involved in the pathogenesis of asthma
remain unclear, roles for oxidative/nitrosative stress, epithelial cell
apoptosis, and airway inflammation have been documented. Cer-
amide is a sphingolipid with potent proinflammatory and proapop-
totic properties. This study aimed at determining whether in-
creased formation of ceramide contributes to the development of
airway inflammation and hyper-responsiveness, using a well char-
acterized in vivo model of allergic asthmatic response and airway
inflammation in ovalbumin-sensitized guinea pigs. Aerosol admin-
istration of ovalbumin increased ceramide levels and ceramide
synthase activity in the airway epithelium associated with respira-
tory abnormalities, such as cough, dyspnea, and severe broncho-
constriction. These abnormalities correlated with nitrotyrosine for-
mation in the airway epithelium and oxidative/nitrosative stress,
epithelial cell apoptosis, and airway inflammation evident by the
infiltration of neutrophils and eosinophils in lung tissues, mast cell
degranulation, and release of prostaglandin D2 and proinflamma-
tory cytokines. Inhibition of de novo ceramide synthesis with the
competitive and reversible inhibitor of ceramide synthase fumoni-
sin B1 (0.25, 0.5 and 1 mg/kg b.wt.), given i.p. daily for 4 days
before allergen challenge, attenuated nitrotyrosine formation and
oxidative/nitrosative stress, epithelial cell apoptosis, and airway
inflammation while improving the respiratory and histopathologi-
cal abnormalities. These results implicate ceramide in the devel-
opment of allergic asthmatic response and airway inflammation.
Strategies aimed at reducing the levels of ceramide and down-
stream events should yield promising novel anti-asthmatic agents.
Asthma is defined by airway inflammation and remodeling
and bronchial hyper-responsiveness (Busse and Lemanske,
2001). The role of inflammation in asthma is well estab-
lished, and neutrophils, eosinophils, and mast cells within
the lung have been shown to have pivotal roles for the
initiation and maintenance of airway inflammation (An-
dreadis et al., 2003; Barnes, 2004). Besides the classical
allergen-dependent pathways, reactive oxygen and nitro-
gen species produced during airway inflammation activate
these cells to release histamine, prostaglandins, leukotri-
enes, proteases, and cytokines, which exacerbate the re-
sponse and directly participate to the pathogenesis of asthma
(Andreadis et al., 2003; Comhair et al., 2005). In experimen-
tal models, reactive oxidant species reproduce multiple
pathophysiologic asthmatic hallmarks: bronchoconstriction,
-adrenergic dysfunction, cytokine production, mucus hyper-
secretion, microvascular leak and edema, epithelial damage
and sloughing, airway remodeling, and hyper-responsiveness
(Andreadis et al., 2003; Comhair et al., 2005). In support of
these data, bronchial obstruction in human asthma is asso-
ciated with an increased spontaneous and stimulus-induced
production of oxygen free radicals by inflammatory cells in
airway lumen (Calhoun et al., 1992).
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Ceramide is a sphingolipid with powerful proapoptotic and
proinflammatory properties and has been implicated in oxi-
dative/nitrosative stress (Huwiler et al., 2000; Pettus et al.,
2002; Kolesnick and Fuks, 2003). Ceramide is generated by
enzymatic hydrolysis of sphingomyelin by sphingomyeli-
nases, the so-called sphingomyelin pathway. Alternatively,
de novo ceramide can be synthesized by serine palmitosyl-
transferase and ceramide synthase, and it is stimulated by
numerous chemotherapeutics and cytokines, which cause a
sustained elevation of ceramide levels (Huwiler et al., 2000;
Kolesnick, 2002). Steady-state availability of ceramide is reg-
ulated by ceramidases that convert ceramide to sphingosine
by catalyzing the hydrolysis of its amide group (Huwiler et
al., 2000; Kolesnick, 2002). The importance of ceramide acti-
vation to inflammation derives from activation of protein
kinases and phosphatases in diverse downstream pathways
(Huwiler et al., 2000) and from its generation of additional
second messengers such as sphingosine 1-phosphate (S1P)
(Le Stunff et al., 2004). Thus, S1P generated upon phosphor-
ylation of sphingosine by sphingosine kinase is the natural
ligand for a family of G protein-coupled receptors originally
termed endothelial differentiation genes and recently re-
named S1P receptors (S1Pr). Five distinct SIPrs have been
identified, although selective receptor antagonists have not
been reported (Chun et al., 2002). These receptors couple to
different G proteins and elicit a wide array of cellular re-
sponses relevant to airway inflammation (Spiegel and Mil-
stien, 2003). An involvement of S1P in asthma has been
recently reported in animal models (Roviezzo et al., 2007)
and humans (Roviezzo et al., 2004). Considering the impor-
tance of epithelial apoptosis in asthma, ceramide is well
established as a major proapoptotic mediator following radi-
ation, chemotherapeutics, or exposure to proinflammatory
cytokines, including TNF-, IL-1, IL-6, and oxidative/nitro-
sative stressors (Huwiler et al., 2000; Kolesnick, 2002; Pettus
et al., 2002). Proapoptotic effects of ceramide involve multiple
mechanisms, such as activation of the kinase suppressor of
Ras (Zhang et al., 2002), stimulation of protein phosphatases
1 and 2a (Chalfant et al., 2002), increased cathepsin D activ-
ity (Heinrich et al., 2000), and direct alteration of plasma and
mitochondrial membrane signaling properties by oxidative/
nitrosative stress (Siskind et al., 2002; Petrache et al., 2005).
In further support of ceramide as a proinflammatory me-
diator, reduced inflammatory responses have been described
through pharmacological manipulation of ceramide synthe-
sis, inhibition of the sphingomyelinase or de novo pathways,
and attenuated synthesis of TNF-, IL-1, and IL-6 as well
as reactive oxygen species (Won et al., 2004). Furthermore,
ceramide has been reported to promote oxidative stress and
enhance expression of endothelial and inducible nitric-oxide
synthases (Won et al., 2004) and cyclooxygenase-2 (Newton
et al., 2000). Furthermore, ceramide-induced activation of
the transcription factor NF-B and p38 kinase amplify the
production of several inflammatory mediators and adhesion
molecules (Won et al., 2004). Therefore, it is not surprising
that both preclinical and clinical studies support a causal role
for ceramide in other conditions characterized by inflamma-
tion, oxidative/nitrosative stress, and apoptosis, such as ra-
diation-induced injury (Kolesnick and Fuks, 2003), sepsis
(Delogu et al., 1999), acute lung injury (Goggel et al., 2004),
and emphysema (Petrache et al., 2005).
Collectively, these findings led us to hypothesize the par-
ticipation of ceramide as a novel signaling lipid in asthma.
Using a well characterized guinea pig model of allergic asth-
ma-like reaction (Suzuki et al., 2004; Masini et al., 2005), our
findings show that increased levels of ceramide contribute to
functional, biochemical, and histological changes associated
with allergic airway inflammation and dysfunction and con-
sequently support a role of this lipid mediator in asthma.
Materials and Methods
Animals
Male Hartley albino guinea pigs were used. They were purchased
from a commercial dealer (Rodentia, Bergamo, Italy) and quaran-
tined for 7 days at 22 to 24°C with a 12-h light/12-h dark cycle before
use. The experimental protocol was designed in compliance with the
recommendations of the European Economic Community (86/609/
CEE) for the care and use of laboratory animals and in agreement
with the Good Laboratory Practice. It was approved by the animal
care committee of the University of Florence (Florence, Italy) where
all of the in vivo experiments were carried out. At the end of the
treatment, the animals weighed 350 to 400 g.
Animal Sensitization and Treatments
The guinea pigs were divided into six experimental groups with
n  10 animals per group.
Group 1. Animals were injected with isotonic saline (5 ml/kg
b.wt., i.p., plus 5 ml/kg b.wt. s.c.) and 18 days later received an
aerosol of ovalbumin (OVA; Fluka, Buchs, Switzerland) dissolved in
saline (5 mg/ml) and used as negative controls. They are referred to
as naive OVA-challenged animals.
The remaining guinea pigs were sensitized with 100 mg/kg b.wt.
i.p. plus 100 mg/kg b.wt. s.c. OVA dissolved in saline (20 mg/ml).
After 18 days, they were challenged with an OVA aerosol (5 mg/ml
saline) to verify sensitization by evaluation of allergen-elicited respi-
ratory changes, as described below. The animals were withdrawn
from antigen exposure at the first signs of respiratory abnormalities.
The guinea pigs reactive to the inhaled antigen were used for the
further experiments. By this protocol, only three of 50 animals failed
to develop sensitization. Three days later, the sensitized guinea pigs
were divided in the following groups.
Group 2. Animals were treated with a subcutaneous injection (0.5
ml) of PBS for 4 days before undergoing the provocation test with an
aerosol of saline alone. These are referred to as the sensitized,
unchallenged group.
Group 3. Animals were treated with a subcutaneous injection (0.5
ml) of PBS for 4 days before undergoing the provocation test with
aerosolized OVA (5 mg/ml saline). These are referred to as the
sensitized OVA-challenged group.
Groups 4 to 6. Animals were treated with a subcutaneous injec-
tion (0.5 ml) of fumonisin B1 (FB1; Sigma-Aldrich, Milan, Italy), a
competitive and reversible inhibitor of ceramide synthase, dissolved
in PBS as vehicle, and tested over three daily doses (0.25, 0.5, and 1
mg/kg b.wt.) for 4 days before undergoing the provocation test with
aerosolized OVA. These are referred to as the sensitized, FB1-
treated OVA-challenged group.
Challenge with Inhaled OVA and Evaluation of Respiratory
Activity
Five guinea pigs from all groups were individually placed in an
airtight transparent whole-body plethysmographic chamber, as de-
scribed previously (Suzuki et al., 2004; Masini et al., 2005). The
changes in inner pressure in the respiratory chamber induced by
breathing were monitored with a high-sensitivity pressure trans-
ducer (Battaglia-Rangoni, Bologna, Italy) connected to a PC2400A
channel polygraph (Battaglia-Rangoni). Upon breath stabilization,
usually occurring within 30 to 60 s, guinea pigs were challenged with
Ceramide and Allergic Asthma 549
 at A
SPET Journals on N
ovem
ber 17, 2016
jpet.aspetjournals.org
D
ow
nloaded from
 
OVA aerosol for 10 s. Animals from the naive group were included in
the aerosol challenge to reveal possible breath alterations due to
nonspecific stimulation of the airways by the aerosol droplets. The
respiratory activity of the animals subjected to the different treat-
ments was monitored for 10 min after the onset of aerosol adminis-
tration and classified according to the criteria reported previously
(Masini et al., 2005). In particular, cough was assumed as a transient
change in the pressure (a rapid inspiration followed by a rapid
expiration), whereas dyspnea was assumed as a series of irregular
breaths of abnormally elevated frequency (tachypnea) and amplitude
or as repeated gasping. Movements of the guinea pigs were visually
monitored by two trained observers who were blinded to group as-
signment of the animals. In this way, any motion- and sneezing-
related changes in the inner pressure of the body chamber could also
be disregarded. The following parameters were evaluated: i) latency
time for the first cough stroke (seconds); ii) cough severity, the
product of cough frequency (cough strokes per minute), and mean
cough amplitude (excess pressure over the normal breath); and iii)
latency time for the onset of dyspnea (seconds).
Measurement of Airway Bronchoconstriction
Anesthetized guinea pigs from each group (n  5) above were
mechanically ventilated by a constant volume method as reported
previously (Masini et al., 2005). Animals were injected with 100
mg/kg b.wt. sodium pentothal (Abbott, Latina, Italy) to induce anes-
thesia and abolish natural respiration. Body temperature was mon-
itored continuously and maintained constant at 37°C. The trachea
was cannulated with a polyethylene tube (inner diameter, 2 mm),
and the animals were ventilated with a small-animal respirator
(Harvard, Edenbridge, UK), adjusted to deliver a tidal volume of 10
ml/kg at a rate of 60 strokes/min. Changes in lung resistance to
inflation (pressure at the airway opening; PAO), specifically the
lateral pressure of the inlet air tube, were registered by a pressure
transducer connected to a polygraph (Battaglia-Rangoni). After 10-
min stabilization, the basal inflation pressure was measured. Each
animal was then exposed to an OVA aerosol for 1 min through the
tracheal inlet air pipe. Changes in inflation pressure, which are
directly related to airway resistance, were recorded for 10 min after
the beginning of OVA aerosol and expressed as percentage changes
over the basal values. These animals were also used for collection of
bronchoalveolar lavage fluid, as detailed below.
Post-Mortem Analyses
At the end of the breath recording period, the animals were re-
moved from the plethysmographic chamber, and they were killed by
decapitation 50 min later (i.e., 1 h after aerosol administration). The
gross appearance of the lungs, liver, and kidneys was examined. No
macroscopic alterations of these organs that could be related to a
toxic effect of FB1 treatment were observed. Lung tissue samples
from each animal from the middle and the lower lobes were taken for
biochemical and morphological analyses, as described below. Before
opening the thorax, in some animals, bronchoalveolar lavage fluids
were obtained by insertion of a cannula into the trachea and instil-
lation of 3 ml of PBS, pH 7.4. In the animals used for measurement
of airway bronchoconstriction, bronchoalveolar fluid was collected
after three flushes into the bronchial tree and centrifuged at 1100g
for 30 min. The cell-free supernatant was collected, and its volume
was measured and frozen at 70°C until needed.
Histologic and Morphometric Analyses
Lung tissue samples, two from each animal, were fixed by immer-
sion in Mota fluid (50% ethanol in water, 0.5% acetic acid, and 15%
basic lead acetate) and embedded in paraffin. This fixative solution
allows a rapid infiltration of the tissue, with only minimal artifactual
shrinking, thus providing a tissue morphology, which is representa-
tive of the lung features in vivo. Lung tissue sections, 5 m thick,
were used for morphometric analysis, as reported previously (Masini
et al., 2005).
A first series of determinations was carried out on hematoxylin
and eosin-stained sections to evaluate the surface area of alveolar air
spaces. In each guinea pig, determinations were performed on tissue
sections cut from the two different lung samples, examined with a
10 objective. Four randomly chosen microscopic fields per animal
(two fields per section) were analyzed. At the chosen magnification,
each field corresponds to a tissue area of 570,224 m2 that includes
an average of 300 alveolar profiles. The same tissue sections were
used to evaluate the surface area of bronchial lumina selected by: i)
histological appearance of small-sized muscular bronchi; and ii)
transverse or slightly oblique cross-section. In each guinea pig, mea-
surements were carried out on four to six randomly chosen bronchi
from the tissue sections cut from the two different lung samples
examined with a 20 objective. Digital images of the microscopic
fields to be analyzed were recorded, and surface area measurements
were carried out using the Scion Image Beta 4.0.2 image analysis
program (Scion Corp., Frederick, MD) upon the appropriate thresh-
old to include only blank tissue-free air spaces. The mean values
(S.E.M.) of alveolar and bronchial luminal areas were then calcu-
lated for each experimental group.
A second series of determinations was carried out on sections
stained with Astra blue (Fluka, Buchs, Switzerland) to evaluate the
optical density of lung-mast cells, which is related to the content of
secretory granules. In each guinea pig, determinations were per-
formed on tissue sections cut from the two different lung samples,
according to the method described previously for similar purposes
(Masini et al., 2005). The mast cells were viewed by the same image
analysis device described above, using a 100 oil immersion objec-
tive. Measurements of optical density were carried out on selected
mast cell profiles using the previously reported program. In each
animal, 30 different mast cells, 15 from each lung sample, were
analyzed, and the mean optical density value (S.E.M.) was then
calculated for the entire experimental group.
A third series of determinations was carried out on sections im-
munostained with anti-major basic protein (MBP), a marker for
eosinophils. Sections were treated with 0.1% trypsin for 10 min to
retrieve antigen and then with 0.3% H2O2 (v/v) in 60%methanol (v/v)
to quench endogenous peroxidase and finally incubated overnight
with mouse monoclonal anti-human eosinophil MBP antibodies
(clone BMK13; Chemicon, Temecula, CA; 1:50 in PBS). Immune
reaction was revealed by the indirect immunoperoxidase method
(Vectastain Elite kit; Vector Laboratories, Burlingame, CA), using
3,3-diaminobenzidine as chromogen. As negative controls, sections
incubated with only the primary or the secondary antisera were
used. In each guinea pig, the number of MBP-positive eosinophils
was counted in 10 randomly chosen microscopic fields at a 200 final
magnification (test area: 72,346 m2). Values obtained from two
different observers were averaged.
Immunohistochemical Analysis of Ceramide and
Nitrotyrosine
Lung tissues were fixed in paraformaldehyde (4% wt/vol) in 0.1 M
PBS, pH 7.4, for 2 h and processed to paraffin sections. After depar-
affinization, the slides were treated in 2% citric acid buffer, pH 6.8,
for 5 min in microwave oven to retrieve antigens, blocked in 10% goat
serum in PBS, and incubated with monoclonal anti-ceramide (1:50;
Sigma-Aldrich) or anti-nitrotyrosine antibodies (1:100; Upstate Bio-
technology, Lake Placid, NY) at 4°C overnight. Immune reaction was
revealed by goat anti-mouse IgG conjugated with biotin (1:200 dilu-
tion; Vector Laboratories) followed by incubation with ABC complex
(1:200 dilution; Vector Laboratories), according to the manufactur-
er’s instructions. Negative controls were carried out by omitting the
primary or the secondary antibodies. The sections were counter-
stained with hematoxylin before mounting.
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Ceramide Synthase Activity Assay
Approximately 100 mg of lung tissue homogenates were incubated
with [3H]palmytic acid (2.5 Ci/ml; Amersham, Buckinghamshire,
UK) for 1 h. Lipids were extracted with ice-cold methanol containing
2% acetic acid and 5% chloroform and resolved using thin-layer
chromatography. Lipids comigrating with standards were scraped
and quantified by lipid scintillation counting. Ceramide was mea-
sured on the lipidic extracts using the diacyl-glycerol kinase assay.
Lung ceramide content was expressed as disintegrations per minute
per milligrams of proteins.
DNA Nicking Assay for Apoptosis in Airway Epithelial
Cells
Lung tissue specimens from guinea pigs were evaluated for cell
death by the in situ apoptosis detection kit AP (Roche Diagnostics,
Indianapolis, IN), based on the terminal deoxynucleotidyl trans-
ferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay. Ap-
optotic cells in lung tissue sections were visualized by labeling DNA
strand breaks by TdT, which catalyzes polymerization of labeled
nucleotides to free 3-OH DNA ends in a template-independent man-
ner. The detection of the incorporated fluorescein was carried out by
an anti-fluorescein antibody conjugated with alkaline phosphatase,
which is converted by Vector Red Alkaline Phosphatase Substrate K
(Vector Laboratories) or by nitro blue tetrazolium (NBT)/5-bromo-4-
chloro-3-indolyl phosphate (Roche Diagnostics). From each biopsy, at
least four bronchiolar profiles were evaluated under a light micro-
scope at a 20 magnification for TUNEL-positive cells. The percent-
age is calculated as the number of positive cells per total number of
bronchial epithelial cells.
Determination of Caspase-3 Activity
The activity of caspase-3 was determined using the Ac-Asp-Glu-
Val-Asp-AMC (Ac-DEVD-AMC; Bachem, Bubendorf, Switzerland)
fluorescent substrate, according to Stennicke and Salvesen (1997).
Lung tissue samples were homogenized with 10 mM HEPES, pH
7.4, containing 0.5% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propane-sulfonate, 42 mM KCl, 5 mM MgCl2, 1 mM dithiothreitol
(DTT), 1 mM phenylmethylsulfonyl fluoride, 2 g/ml leupeptin,
and 1 g/ml pepstatin A. The homogenate was then centrifuged at
10,000g for 10 min. The supernatants (containing 250 g of total
protein) were incubated with 40 M Ac-DEVD-AMC for 60 min at
37°C. Substrate cleavage was monitored fluorometrically (Spec-
trofluo JY3 D; Jobin Yvon, Paris, France) at 380-nm excitation
and 460-nm emission wavelengths. Data are expressed as arbi-
trary units per milligram of proteins. One unit of enzyme activity
is defined as the amount of enzyme required to liberate 40 mol of
Ac-DEVD-AMC upon 60 min at 37°C.
Determination of Lung Tissue Myeloperoxidase Activity
Myeloperoxidase (MPO) activity, an indicator of leukocyte accu-
mulation, was determined as described previously (Masini et al.,
2005). Lung tissue samples of approximately 100 mg were homoge-
nized in a solution containing 0.5% hexadecyltrimethylammonium
bromide dissolved in 10 mM potassium phosphate buffer, pH 7, and
then centrifuged for 30 min at 20,000g at 4°C. An aliquot of the
supernatant was then allowed to react with a solution of tetrameth-
ylbenzidine (1.6 mM; Sigma-Aldrich) and 0.1 mM H2O2. The rate of
change in absorbance was measured spectrophotometrically at
650-nm wavelength. Myeloperoxidase activity was defined as the
quantity of enzyme degrading 1 mol of hydrogen peroxide per
minute at 37°C (expressed in milliunit per milligram of wet tissue).
Determination of Lung Tissue Malonyldialdehyde
Production
This was determined by measurement of the chromogen obtained
from the reaction of malonyldialdehyde (MDA) with 2-thiobarbituric
acid (Masini et al., 2005). Approximately 100 mg of lung tissue were
homogenized with 1 ml of 50 mM Tris-HCl buffer containing 180 mM
KCl and 10 mM EDTA, final pH 7.4. 2-Thiobarbituric acid (0.5 ml,
1% w/v; Sigma-Aldrich) in 50 mM NaOH and 0.5 ml of HCl (25% w/v
in water) was added to 0.5 ml of sample. The mixture was placed in
test tubes, sealed with screw caps, and heated in boiling water for 10
min. After cooling, the chromogen was extracted in 3 ml of 1-butanol,
and the organic phase was separated by centrifugation at 2000g for
10 min. The absorbance of the organic phase was read spectropho-
tometrically at 532-nm wavelength. The values are expressed as
nanomole of thiobarbituric acid-reactive substances (MDA equiva-
lents) per milligram of protein, using a standard curve of 1,1,3,3-
tetramethoxypropane (Sigma-Aldrich).
Determination of 8-Hydroxy-2-deoxyguanosine
DNA isolation was performed according to Masini et al. (2005).
Lung samples were homogenized in 1 ml of 10 mM PBS, pH 7.4,
sonicated on ice for 1 min, added with 1 ml of 10 mM Tris-HCl buffer,
pH 8, containing 10 mM EDTA, 10 mM NaCl, and 0.5% SDS, incu-
bated for 1 h at 37°C with 20 g/ml RNase I (Sigma-Aldrich), and
incubated overnight at 37°C under argon in the presence of 100
g/ml proteinase K (Sigma-Aldrich). The mixture was extracted with
chloroform/isoamyl alcohol (10/2 v/v). DNA was precipitated from the
aqueous phase with 0.2 volumes of 10 M ammonium acetate, solu-
bilized in 200 l of 20 mM acetate buffer, pH 5.3, and denatured at
90°C for 3 min. The extract was then supplemented with 10 IU of P1
nuclease (Sigma-Aldrich) in 10 l and incubated for 1 h at 37°C with
5 IU of alkaline phosphatase (Sigma-Aldrich) in 0.4 M phosphate
buffer, pH 8.8. All of the procedures were performed in the dark
under argon. The mixture was filtered by an Amicon Micropure-EZ
filter (Millipore Corporation, Billerica, MA), and 50 l of each sample
was used for 8-hydroxy-2-deoxyguanosine (8-OHdG) determination
using a Bioxytech enzyme immunoassay kit (Oxis, Portland, OR),
following the instructions provided by the manufacturer. The values
are expressed as nanogram of 8-OHdG per milligram of protein.
Measurement of MnSOD Activity
Lung samples were homogenized with 10 mM PBS, pH 7.4, soni-
cated on ice for 1 min, and centrifuged at 100g for 10 min. The assay
of MnSOD activity was performed on the supernatants by the
method described by Masini et al. (2005). The assay is based on
SOD-induced inhibition of the conversion of NBT into a blue tetra-
zolium salt mediated by superoxide radicals generated by xanthine
oxidase. The reaction was performed in sodium carbonate buffer (50
mM), pH 10.1, containing 0.1 mM EDTA, 25 M NBT (Sigma-
Aldrich), 0.1 mM xanthine, and 2 nM xanthine oxidase (Roche Diag-
nostics). The rate of reduction of NBT was monitored with a
PerkinElmer spectrophotometer set (PerkinElmer Life and Analyti-
cal Sciences, Boston, MA) at 560-nm wavelength. The amount re-
quired to inhibit the rate of reduction of NBT by 50% was defined as
1 unit of SOD activity. Specific MnSOD activity was calculated by
inhibiting total SOD activity preincubating the sample for 30 min
with 2 mM sodium cyanide. Values are expressed as milliunits per
milligram of proteins.
Measurement of PARP Activity
PARP-1 activity was measured as described previously (Suzuki et
al., 2004). Lung tissues were homogenized in 50 mM Tris-HCI, pH 8,
4°C, containing 0.1% Nonidet P-40, 200 mM KCl, 2 mM MgCl2, 50
M ZnCl2, 2 mM DTT, and protease inhibitors (1 mM phenylmeth-
ylsulfonyl fluoride, 5 l/ml leupeptin and antipain). Samples were
then centrifuged, and 10 l of each supernatant were incubated for
5 min at 25°C with 2 l of [3H]NAD (specific activity 25 Ci/nmol;
Amersham) in 50 mM Tris-HCI, pH 8, containing 20 mM MgCl2, 1
mM DTT, and 20 M NAD in the absence or presence of activated
calf thymus DNA in the final volume of 100 l. The reaction was
stopped by the addition of 5% trichloroacetic acid. Samples were
filtered, and the radioactivity in the acid-insoluble fraction was
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counted by a Beckman LS1801 liquid scintillation spectrometer.
PARP activity estimated without activated DNA in the mixture was
assigned as “endogenous” activity. Activity estimated in the presence
of activated DNA in the assay mixture was assigned as “total”
activity of PARP. Ratio between endogenous and total activity was
considered as the measure of PARP activity in the tissues.
Determination of PGD2 and TNF- in Bronchoalveolar
Lavage Fluid
Production of PGD2, the major cyclooxygenase product generated
by activated mast cells during allergic response, and TNF- were
measured using a commercial enzyme-linked immunosorbent assay
kits (Cayman Chemical, Ann Arbor, MI), following the protocol pro-
vided by the manufacturer. Results are expressed as nanogram of
PGD2 on TNF per milliliter of bronchoalveolar lavage fluid.
Statistical Analysis
Data are expressed as mean  S.E.M. Statistical analysis was
performed by one-way analysis of variance, followed by the Stu-
dent’s-Newman-Keuls multiple comparison post-hoc test; p  0.05
was considered significant. Calculations were done using a Graph-
Pad Prism 2.0 statistical program (GraphPad Software, San Diego,
CA).
Results
Ceramide Contributes to Respiratory Abnormalities
and Hyper-Responsiveness in Actively Sensitized
Guinea Pigs. As detected by immunohistochemistry, aerosol
administration of OVA increased lung ceramide levels in
sensitized but not in naive guinea pigs (Fig. 1, A and B).
Staining for ceramide was stronger in the airway epithelium
(Fig. 1B). Increased ceramide was paralleled by up-regula-
tion of ceramide synthase activity (Fig. 2) and was associated
with marked abnormalities in the respiratory pattern, con-
sisting of a significant reduction of cough latency and onset of
dyspnea (Fig. 3A) and a significant increase in cough severity
score (Fig. 3B). Likewise, experiments with mechanically
ventilated animals revealed that, in sensitized but not naive
animals, OVA challenge induced a prompt, clear-cut increase
in inflation pressure (PAO), indicating the occurrence of an
immediate asthmatic response (Fig. 3C). Such functional ab-
normalities were accompanied by histopathological abnor-
malities. A representative micrograph of lung tissue is shown
in Fig. 4A. Indeed, macroscopic examination of the lungs
showed prominent changes consisting mainly of marked
swelling of the pulmonary lobes due to air accumulation.
Sectioning of trachea or of main bronchi did not cause lung
deflation, thus indicating that obstruction of peripheral bron-
chi had occurred. Light microscopy of lung tissue showed that
the intrapulmonary bronchioli and respiratory air spaces of
naive guinea pigs had a normal appearance. In particular,
intrapulmonary bronchioli showed open lumina, with bron-
chial mucosa forming short folds, and alveolar air spaces
were evenly small-sized (Fig. 4A, panel A). On the other
hand, in the sensitized, vehicle-treated guinea pigs chal-
lenged with OVA, we observed a reduction of the lumen of
intrapulmonary bronchi and, in large areas of the lung pa-
renchyma, a marked dilation of the alveolar air spaces due to
accumulation of entrapped air (Fig. 4A, panel B). Further-
more and as shown by morphometric analysis, the luminal
area of the alveolar air spaces was significantly increased,
whereas the bronchiolar area was significantly reduced post-
antigen challenge in sensitized animals (Fig. 4C).
Inhibition of de novo ceramide synthesis with FB1 (1 mg/
kg), a competitive and reversible inhibitor of ceramide syn-
thase (Petrache et al., 2005), attenuated the formation of
ceramide as measured by immunohistochemistry (Fig. 1C).
In keeping with these results, OVA challenge in sensitized
guinea pigs increased the enzymatic activity of ceramide
synthase, and FB1 pretreatment significantly reduced this
phenomenon (Fig. 2). FB1 also improved in a dose-dependent
manner (0.25–1 mg/kg) the respiratory abnormalities (Fig. 3,
A and B), attenuated hyper-responsiveness (Fig. 3C), and
improved overall histopathological abnormalities (Fig. 4,
A–C). Thus, as can be seen in Fig. 4A (panel C), the intrapul-
monary bronchi did not show appreciable signs of constric-
tion, and the alveolar air spaces were not dilated. Morpho-
metric analysis confirmed the visual observations that FB1
prevented in a dose-dependent manner (0.25–1 mg/kg) bron-
chiolar constriction and pulmonary air space inflation (Fig. 4,
B and C).
Ceramide Inhibition Attenuates Oxidative and Ni-
trosative Stress. Ceramide increased concurrently with
markers of oxidative and nitrosative stress as evidenced by
the appearance in lung tissues of nitrotyrosine, an indicator
of the formation of nitrating oxidants (Fig. 1E), and by the
increased formation of MDA (Fig. 5A), a well known byprod-
uct of oxidative stress-induced lipid peroxidation of cell mem-
Fig. 1. Compared to OVA-challenged naive animals (A and D), OVA
challenge in sensitized guinea pigs pretreated with PBS leads to forma-
tion of ceramide and nitrotyrosine, as detected by immunohistochemistry
(B and E). Pretreatment with FB1 (1 mg/kg) before OVA challenge blocks
ceramide staining (C and F). Images are representative of at least three
different experiments.
Fig. 2. Ceramide synthase activity in lung tissue homogenates is up-
regulated in OVA-challenged, sensitized guinea pigs (SOVA) compared
with OVA-challenged naive animals (NOVA). FB1 pretreatment of
OVA-challenged, sensitized animals significantly reduces the enzyme
activity. Values are mean  S.E.M. of four different experiments. , p 
0.01 versus NOVA; , p  0.001 versus SOVA.
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branes. Furthermore, OVA challenge led to enzymatic inac-
tivation of MnSOD (Fig. 5B), increased the levels of 8-OHdG
(Fig. 5C), a marker of oxidative DNA damage, and increased
PARP activity (Fig. 5D). FB1 (1 mg/kg) attenuated nitroty-
rosine formation (Fig. 1F) and dose-dependently (0.25–1 mg/
kg) restored the enzymatic activity of MnSOD and decreased
oxidative DNA damage, PARP activity, and MDA formation
(Fig. 5, A–D).
Ceramide Inhibition Attenuates Apoptosis. OVA chal-
lenge in sensitized animals increases the activity of caspase-3
(Fig. 6), supporting the presence of apoptosis. Indeed, no
TUNEL-positive cells were detected in OVA-challenged naive
animals (Fig. 7A), whereas OVA challenge in sensitized guinea
pigs led to the appearance of several airway epithelial cells
Fig. 3. Compared to OVA-challenged naive (NOVA) or in sensitized and
unchallenged (S) animals, OVA challenge in sensitized guinea pigs
(SOVA) led to a reduction of the latency time for cough and dyspnea (A)
and to an increase in cough severity (B). As shown in C, FB1 also
inhibited in a dose-dependent manner (0.25–1 mg/kg) OVA-induced bron-
choconstriction in sensitized, mechanically ventilated guinea pigs, eval-
uated 10 min after OVA aerosol. PAO is expressed as percentage change
over basal inflation pressure before OVA challenge, assumed as 100%.
Data are expressed as mean  S.E.M. of five animals per experimental
group. , p  0.01 versus OVA-challenged naive animals; #, p  0.01
versus OVA-challenged, sensitized animals in the absence of FB1 or
unchallenged, sensitized animals.
Fig. 4. A, representative lung tissue micrographs from OVA-challenged,
naive guinea pigs (panel A), OVA-challenged, sensitized guinea pigs
pretreated with PBS (panel B) and OVA-challenged, sensitized guinea
pigs pretreated with the highest dose of FB1 (1 mg/kg) (panel C). Com-
pared with A, a marked dilation of respiratory air spaces and reduction of
bronchiolar lumen is seen in B but these alterations are not present in the
FB1-treated group (C). Hematoxylin and eosin staining. B and C, mor-
phometric analysis of luminal area of respiratory air spaces (B) and
bronchioli (C). FB1 dose-dependently reduces the lung tissue abnormal-
ities induced by OVA challenge in sensitized guinea pigs. , p  0.001
versus naive animals; #, p  0.001 versus OVA-challenged, sensitized
animals.
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undergoing apoptosis (Fig. 7, B and D). FB1 attenuated in a
dose-dependent fashion (0.25–1 mg/kg) caspase-3 activation
(Fig. 6) and significantly reduced epithelial cell apoptosis (0.5–1
mg/kg) (Fig. 7, A and B).
Ceramide Inhibition Attenuates Inflammation. Com-
pared to naive and OVA-challenged animals, the increase
in ceramide observed in sensitized animals after OVA chal-
lenge was associated with a clear-cut inflammatory response
characterized by mast cell degranulation (Fig. 8A) and neu-
trophilic and eosinophilic infiltration in lung tissue, as mea-
sured by increases in MPO levels and MBP-positive cells,
respectively (Fig. 8, B and C). Inflammatory cells were
mostly located around the bronchi and within the stromal
septa. Antigen challenge also led to increased levels of PGD2,
the major mast cell-derived prostaglandin, in bronchoalveo-
lar lavage fluids and of TNF-, a proinflammatory cytokine
Fig. 5. Compared to OVA-challenged
naive (NOVA) or sensitized and un-
challenged (S) animals, OVA challenge
in sensitized guinea pigs (SOVA)
leads to increased formation of MDA
(A), inactivation of MnSOD (B), en-
hanced generation of 8-OHdG (C), and
increased PARP activity (D). These bio-
chemical changes are reduced in a dose-
dependent fashion by FB1 (0.25–1 mg/
kg). Data are expressed as mean 
S.E.M. of five animals per experimental
group. , p  0.01 versus OVA-chal-
lenged naive animals; #, p  0.05 ver-
sus OVA-challenged, sensitized ani-
mals in the absence of FB1 or non-OVA-
challenged, sensitized animals.
Fig. 6. Compared to OVA-challenged naive (NOVA) or in sensitized and
unchallenged (S) animals, OVA challenge in sensitized guinea pigs
(SOVA) increased caspase-3 activity, and this was blocked in a dose-
dependent fashion by FB1 (0.25–1 mg/kg). Data are expressed as mean 
S.E.M. of five animals per experimental group. , p  0.01 versus OVA-
challenged, naive animals; #, p  0.05 versus OVA-challenged, sensitized
animals in the absence of FB1 or sensitized, unchallenged animals.
Fig. 7. Immunohistochemical analysis of apoptosis in airway epithelial
cells. Increased numbers of TUNEL-positive epithelial cells can be seen
(red nuclei) in OVA-challenged, sensitized animals (B) compared with
OVA-challenged naive animals (A). FB1 (0.5–1 mg/kg) leads to a reduc-
tion of the amount of TUNEL-positive cells (C). The histogram (D) shows
the mean  S.E.M. of percent TUNEL-positive epithelial cells. , p 
0.05; , p  0.01.
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(Fig. 8D). The above signs of inflammatory response were
consistently reduced by FB1 in a dose-dependent fashion
(0.25–1 mg/kg) (Fig. 8, A–D).
Discussion
Asthma is a chronic inflammatory disease of the airways
affecting 6 to 7% in the population and accounting for more
than $6.2 billion in direct and indirect costs in the United
States alone (Busse and Lemanske, 2001). The pathophysi-
ology of this disease is complex and not completely clarified,
thus being the object of intensive research efforts. The results
of our studies implicate ceramide as a key signaling mediator
in biochemical events culminating in acute asthmatic re-
sponse and airway inflammation and, ultimately, respiratory
dysfunction.
Antigen challenge in sensitized but not naive guinea pigs
increased ceramide synthase activity, and the amount of immu-
noreactive ceramide in lung tissues, preferentially within the
epithelium, reduced the latency for cough and dyspnea and
significantly increased cough severity. This increase in cer-
amide was associated with the appearance in lung tissues of
nitrotyrosine, an indicator of the formation of nitrating oxi-
dants, and by increased formation of MDA, a byproduct of
oxidative stress-induced lipid peroxidation of cell membranes.
Systemic administration of the ceramide synthase inhibitor
FB1 attenuated the formation of ceramide and significantly
reduced the development of oxidative/nitrosative stress and
respiratory abnormalities. These data provide a link between
ceramide, oxidative/nitrosative stress, and acute asthmatic
response.
Oxidative and nitrosative stress is a key feature of asthma,
and as such, the prominent roles of superoxide, nitric oxide,
and their reaction product peroxynitrite are well recognized
(Comhair et al., 2005). It is noteworthy that we and others
have demonstrated an inverse correlation between produc-
tion of these reactive species and forced expiration volume,
an index of bronchial obstruction, in asthmatics (Calhoun et
al., 1992; Comhair et al., 2005). A key signaling pathway that
favors accumulation of superoxide and thus peroxynitrite is
the enzymatic inactivation of MnSOD (Radi et al., 2001) that
normally degrades superoxide. MnSOD is itself a target for
tyrosine nitration and oxidation (Yamakura et al., 1998) that
leads to loss of enzyme function, subsequent oxidative dam-
age of mitochondrial proteins, and initiation of apoptosis.
Under severe oxidative and nitrosative stress, DNA damage
causes overactivation of the nuclear enzyme PARP, a critical
intracellular mechanism of cell death through both necrotic
and apoptotic pathways (Schreiber et al., 2006). Here we
have shown that FB1 blocked the inactivation of MnSOD and
prevented oxidative DNA damage, PARP and caspase-3 ac-
tivation, and epithelial cell apoptosis. The importance of the
reduction of epithelial cell apoptosis by FB1 is underscored
by the fact that apoptosis has been intimately linked to
airway remodeling and hyper-responsiveness in asthmatics
(Comhair et al., 2005). Taken together, our results suggest
that ceramide induces oxidative/nitrosative stress, resulting
in MnSOD inactivation, thus triggering epithelial cell apo-
ptosis, presumably via PARP and caspase activation. Cer-
amide has been reported to stimulate formation of reactive
oxygen/nitrogen species and to also induce the expression of
the inducible nitric-oxide synthase (Won et al., 2004). It is
interesting to note that, whereas ceramide promotes gener-
ation of these species, superoxide and nitric oxide (and pre-
sumably peroxynitrite) increase steady-state concentrations
of ceramide by activating sphingomyelinases and by increas-
ing the degradation of ceramidases, the enzymes responsible
for ceramide catabolism (Huwiler et al., 2000; Pautz et al.,
Fig. 8. Compared to OVA-challenged
naive (NOVA) or sensitized and un-
challenged (S) animals, OVA challenge
in sensitized guinea pigs (SOVA)
causes mast cell degranulation (A) and
promotes lung tissue infiltration by
neutrophils (B; evaluated by MPO in
tissue homogenates) and eosinophils
(C; evaluated as MBP-positive cells in
lung tissue sections), and increased lev-
els of PGD2 and TNF- (D; measured in
bronchoalveolar lavage fluids). These
events are blocked in a dose-dependent
fashion by FB1 (0.25–1 mg/kg). Data
are expressed as mean  S.E.M. of five
animals per experimental group. , p
0.01 versus OVA-challenged naive ani-
mals; #, p  0.05 versus OVA-chal-
lenged, sensitized animals in the ab-
sence of FB1 or unchallenged,
sensitized animals.
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2002). These events contribute to the overall increase in the
levels of ceramide and thus ceramide-mediated damage. Al-
though the mechanisms by which these reactive oxygen/ni-
trogen species enhance the degradation of ceramidases are
not understood, one potential mechanism may be nitration,
thus facilitating their faster degradation by the ubiquitin/
proteasome pathway (Souza et al., 2000). In endothelial cells,
costimulation with nitric oxide and superoxide synergisti-
cally increase ceramide production and apoptosis (Pettus et
al., 2002), which may contribute to an overall increase in
tissue levels of ceramide and thus ceramide-mediated dam-
age.
Our results suggest that the protective effects of FB1 may
be secondary to attenuation of the inflammatory response, as
evidenced by reductions of mast cell activation and degran-
ulation, neutrophil and eosinophil infiltration, and release of
TNF-. The critical roles of neutrophils, eosinophils, and proin-
flammatory cytokines in the pathogenesis of asthma are known.
Inhibition of neutrophil and eosinophil infiltration attenuates
inflammation associated with late-phase responses and air-
way hyper-responsiveness, whereas mast cell mediators, in-
cluding histamine, PGD2 and TNF-, evoke bronchoconstric-
tion, smooth muscle cell proliferation, and recruitment of
inflammatory cells (Busse and Lemanske, 2001). Ceramide
modulation of these inflammatory responses through oxida-
tive/nitrosative stress may occur upon several mechanisms.
First, superoxide and peroxynitrite induce endothelial cell
damage and increased microvascular permeability (Haglind
et al., 1994) and activate redox-sensitive NF-B and AP-1
that promote the expression of genes encoding for proinflam-
matory and pro-nociceptive cytokines, such as IL-1, TNF-,
and IL-6 (Ndengele et al., 2005), as well as for adhesion
molecules involved in neutrophil and eosinophil recruitment
to inflammatory sites (Salvemini et al., 1999). Second,
superoxide/peroxynitrite promote mast cell degranulation
and histamine release (Masini et al., 2005). Third, super-
oxide/peroxynitrite activate cyclooxygenase enzymes lead-
ing to increased production of prostaglandins. Fourth,
thera-
peutic reduction of oxidative/nitrosative stress with super-
oxide dismutase mimetics and peroxynitrite decomposi-
tion catalysts is anti-inflammatory and tissue-protective
(Salvemini et al., 1999).
In summary, our results have revealed that formation of
ceramide in the lung plays a critical role in the development
of allergic asthma through at least three biochemical path-
ways: 1) oxidative and nitrosative stress; 2) apoptosis of
airway epithelial cells; and 3) local tissue inflammation. Our
study does not provide direct evidence that some of the ob-
served effects could be ascribed to the downstream ceramide
metabolite S1P, although this possibility is not to be ruled
out. S1P is stored in mast cells, platelets, and endothelial and
epithelial cells (Jolly et al., 2002) and is secreted as an
autocrine mediator into the extracellular environment. S1P
activates monocytes, endothelial cells, mast cells, and smooth
muscle cells, mediates eosinophil and lymphocyte infiltra-
tion, and promote airway remodeling and hyper-responsive-
ness (Lee et al., 1999; Ammit et al., 2001; Roviezzo et al.,
2007). In this context, S1P levels increase in the airways of
asthmatic patients after allergen challenge and correlate
with eosinophil number and protein concentration in their
bronchoalveolar lavage fluids (Roviezzo et al., 2004). Multi-
ple S1P receptors have been identified in the lung, includ-
ing S1Pr1 and S1Pr3 (Zhang et al., 1999). Recent studies in
S1Pr3-deficient mice suggested that S1Pr3 receptors ex-
pressed by the bronchial epithelium are responsible for S1P-
mediated pulmonary leakage (Gon et al., 2005). Knowledge of
the relative contribution of each S1P receptor through the
development of selective inhibitors will be critical in under-
standing its importance in asthma. Nevertheless, thera-
peutic strategies aimed at lowering pathologically elevated
concentrations of ceramide in asthma could prevent the for-
mation of both ceramide and S1P, possibly providing a more
favorable endpoint than simply blocking one of the S1P
receptors.
Our data suggest that increased formation of ceramide after
antigen challenge promotes oxidative/nitrosative stress and en-
zymatic inactivation of MnSOD that trigger apoptosis and loss
of airway epithelial cells. Furthermore, ceramide contributes to
the lung inflammatory response by degranulating mast cells,
recruiting neutrophils/eosinophils, and increasing formation of
cytokines. In this paradigm, it is important to consider that
reciprocal relationships exist among the inflammatory re-
sponse, oxidative stress, and activation of the ceramide path-
way, which may sparkle a vicious cycle that amplifies the dis-
ease. In turn, cytokines can stimulate the formation of reactive
oxidative/nitrosative species and activate the de novo ceramide
synthesis pathway (Kolesnik, 2002). The current findings sug-
gest that strategies aimed at reducing in situ levels of ceramide
could interrupt this vicious cycle and be a novel, promising
antiasthmatic therapeutic strategy.
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